Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(8):547-549; doi:10.1093/jnci/94.8.547
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ganz, P. A.
Right arrow Articles by Silverman, D. H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ganz, P. A.
Right arrow Articles by Silverman, D. H. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 8, 547-549, April 17, 2002
© 2002 Oxford University Press

EDITORIAL

Estrogen, Tamoxifen, and the Brain

Patricia A. Ganz, Steven A. Castellon, Daniel H. S. Silverman

Affiliations of authors: P. A. Ganz, University of California at Los Angeles (UCLA) Schools of Medicine and Public Health, and Jonsson Comprehensive Cancer Center at UCLA; S. A. Castellon, Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, and Greater Los Angeles Veterans Administration Health Care System; D. H. S. Silverman, Department of Molecular and Medical Pharmacology, UCLA School of Medicine, and Ahmanson Biological Imaging Center, UCLA.

Correspondence to: Patricia A. Ganz, M.D., Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center, 650 Charles Young Dr. South, Los Angeles, CA 90095–6900 (e-mail: pganz@ucla.edu).

With the aging of the population and the increasing numbers of individuals that are being diagnosed with dementia or milder forms of cognitive dysfunction, there is heightened interest in identifying risk factors and protective factors for this important health problem. A series of recent publications (1–6) have called increased attention within the cancer community to the complaints of memory loss and decreased cognitive abilities from patients in active chemotherapy treatment, as well as of those who have received chemotherapy within the previous several years. The results of these studies (1–6) suggest that neurocognitive testing detects clinically significant, but sometimes subtle, abnormalities in a subset of patients who are exposed to both high-dose and standard-dose chemotherapy treatments. In this issue of the Journal, Ernst and colleagues (7) explored the association between the use of tamoxifen therapy in elderly breast cancer patients . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
C. J. Fabian and B. F. Kimler
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655.
[Full Text] [PDF]